Helius Medical Technologies, Inc. (Canada)

At Helius Canada, we’re using the power of our collective curiosity, talent and experience to change the lives of those affected by mild-to-moderate traumatic brain injury (mmTBI) and mild-to-moderate symptoms from multiple sclerosis (MS). We know how symptoms of mmTBI and MS can marginalize those affected and we’re committed to changing that dynamic through the development of new neurotech treatments that will reset both the standards and expectations of care. Helius Canada is authorized to offer PoNS Treatment™ at licensed clinics across Canada. The novel therapy includes use of the award-winning Portable Neuromodulation Stimulator, or PoNS™ device, combining stimulation of the cranial nerves through the tongue with focused rehabilitation, which may reactivate and change the neural network, compensating for previously lost function.. PoNS Treatment™ is intended for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The device is also intended for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS™ is an investigational device in the EU and Australia and is currently under review for market clearance by the AUS TGA; PoNS™ is not commercially available in the US, EU, or Australia. For more information, please visit https://www.ponstreatment.ca/.

Company’s Keywords: